Advertisement
Advanced Search
To read this article in full, please review your options for gaining access at the bottom of the page.
Article in Press

To view the full text, please login as a subscribed user or purchase a subscription. Click here to view the full text on ScienceDirect.

Figures

Fig. 1

Kaplan–Meier survival analysis showing patients with type B acute aortic dissection with hypoalbuminaemia (serum albumin [SA] ≤ 34 g/L) had significantly worse survival than patients without hypoalbuminaemia.

Abstract

Background

Few studies have reported that serum albumin (SA) levels on admission were associated with increased risk of long-term outcomes in patients with type B acute aortic dissection (AAD). The aim of this study was to investigate the effect of admission levels of SA on survival among patients with type B AAD undergoing endovascular therapy (EVT).

Methods

A total of 131 patients with type B AAD undergoing EVT were retrospectively enrolled and followed up for 2.1 years. They were divided into hypoalbuminemia and non-hypoalbuminemia groups. We analyzed the incidence of in-hospital complications and long-term mortality. Kaplan–Meier curves and multivariable Cox regression analyses were used to investigate the associations between SA levels and survival.

Results

Among 131 type B AAD patients, hypoalbuminemia was detected in 61 (46.6%) at admission. Compared to those without hypoalbuminemia, patients with hypoalbuminemia did not have higher in-hospital complications; however, Kaplan–Meier analysis showed that they did have a significantly lower survival rate (73.8% vs. 92.5%, log-rank χ2 = 9.8, P = .002). Multivariable Cox regression analysis further revealed that hypoalbuminemia was an independent predictor of long-term mortality among patients with type B AAD (hazard ratio, 4.28; 95% confidence interval, 1.36–13.47; P = .013), over 2.1 years.

Conclusions

Hypoalbuminemia is common in type B AAD patients and is independently associated with increased risk of long-term death. Renal dysfunction may be the main pathophysiological mechanism underlying hypoalbuminemia in patients with type B AAD.

To access this article, please choose from the options below

Log In


Forgot password?

Register

Create a new account

Purchase access to this article

Claim Access

If you are a current subscriber with Society Membership or an Account Number, claim your access now.

Subscribe to this title

Purchase a subscription to gain access to this and all other articles in this journal.

Institutional Access

Visit ScienceDirect to see if you have access via your institution.

Related Articles

Searching for related articles..

Advertisement